The data indicated that high levels of FBXL7 transcripts could be an independent factor for predicting an unfavorable risk for cancer recurrence after adjuvant chemotherapy in ovarian cancer patients (Table 1). This evidence concerns the gene FBXL7 and ovarian carcinoma.